438 related articles for article (PubMed ID: 26111826)
1. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study.
Cohen JA; Khatri B; Barkhof F; Comi G; Hartung HP; Montalban X; Pelletier J; Stites T; Ritter S; von Rosenstiel P; Tomic D; Kappos L;
J Neurol Neurosurg Psychiatry; 2016 May; 87(5):468-75. PubMed ID: 26111826
[TBL] [Abstract][Full Text] [Related]
2. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
[TBL] [Abstract][Full Text] [Related]
3. Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
Meng X; Chin PS; Hashmonay R; Zahur Islam M; Cutter G
Contemp Clin Trials; 2015 Mar; 41():69-74. PubMed ID: 25545026
[TBL] [Abstract][Full Text] [Related]
4. Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials.
Derfuss T; Ontaneda D; Nicholas J; Meng X; Hawker K
Mult Scler Relat Disord; 2016 Jul; 8():124-30. PubMed ID: 27456887
[TBL] [Abstract][Full Text] [Related]
5. Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies.
Haas J; Jeffery D; Silva D; Meier DP; Meinert R; Cohen J; Hartung HP
Mult Scler Relat Disord; 2019 Nov; 36():101335. PubMed ID: 31557679
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analyses.
Chinea Martinez AR; Correale J; Coyle PK; Meng X; Tenenbaum N
Adv Ther; 2014 Oct; 31(10):1072-81. PubMed ID: 25245812
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis.
Hua LH; Hersh CM; Morten P; Kusel J; Lin F; Cave J; Varga S; Herrera V; Ko JJ
J Manag Care Spec Pharm; 2019 Apr; 25(4):490-498. PubMed ID: 30917079
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.
Kappos L; O'Connor P; Radue EW; Polman C; Hohlfeld R; Selmaj K; Ritter S; Schlosshauer R; von Rosenstiel P; Zhang-Auberson L; Francis G
Neurology; 2015 Apr; 84(15):1582-91. PubMed ID: 25795646
[TBL] [Abstract][Full Text] [Related]
9. Fingolimod reduces the clinical expression of active demyelinating lesions in MS.
Signoriello E; Landi D; Monteleone F; Saccà F; Nicoletti CG; Buttari F; Sica F; Marfia GA; Di Iorio G; Lus G; Centonze D
Mult Scler Relat Disord; 2018 Feb; 20():215-219. PubMed ID: 29433094
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study.
Saida T; Itoyama Y; Kikuchi S; Hao Q; Kurosawa T; Ueda K; Auberson LZ; Tsumiyama I; Nagato K; Kira JI
BMC Neurol; 2017 Jan; 17(1):17. PubMed ID: 28129749
[TBL] [Abstract][Full Text] [Related]
11. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.
Cohen JA; Barkhof F; Comi G; Izquierdo G; Khatri B; Montalban X; Pelletier J; Eckert B; Häring DA; Francis G
J Neurol; 2013 Aug; 260(8):2023-32. PubMed ID: 23632946
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
13. Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIG
Arnold DL; Banwell B; Bar-Or A; Ghezzi A; Greenberg BM; Waubant E; Giovannoni G; Wolinsky JS; Gärtner J; Rostásy K; Krupp L; Tardieu M; Brück W; Stites TE; Pearce GL; Häring DA; Merschhemke M; Chitnis T;
J Neurol Neurosurg Psychiatry; 2020 May; 91(5):483-492. PubMed ID: 32132224
[TBL] [Abstract][Full Text] [Related]
14. Consistent control of disease activity with fingolimod versus IFN β-1a in paediatric-onset multiple sclerosis: further insights from PARADIG
Deiva K; Huppke P; Banwell B; Chitnis T; Gärtner J; Krupp L; Waubant E; Stites T; Pearce GL; Merschhemke M
J Neurol Neurosurg Psychiatry; 2020 Jan; 91(1):58-66. PubMed ID: 31467033
[TBL] [Abstract][Full Text] [Related]
15. Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis.
Kappos L; Radue EW; Chin P; Ritter S; Tomic D; Lublin F
J Neurol; 2016 Feb; 263(2):354-360. PubMed ID: 26645392
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
Comi G; Kappos L; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Ding N; Cohen JA;
Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
[TBL] [Abstract][Full Text] [Related]
17. Switching to fingolimod in PREFERMS: Effect of treatment history and naïvety on clinical, MRI and treatment satisfaction outcomes
Hunter SF; Thomas FP; Cascione M; Williams IM; Meng X; Schofield L; Weiss JL; Tenenbaum N; Cree BAC;
Mult Scler Relat Disord; 2020 Oct; 45():102346. PubMed ID: 32717684
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
Cohen JA; Comi G; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Huang V; Kappos L;
Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
[TBL] [Abstract][Full Text] [Related]
19. Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience.
D'Amico E; Patti F; Zanghì A; Lo Fermo S; Chisari CG; Zappia M
Expert Rev Clin Pharmacol; 2018 May; 11(5):531-536. PubMed ID: 29521113
[TBL] [Abstract][Full Text] [Related]
20. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]